Advertisement

Letter From the Editor

May 2017

Dear Colleague,

Welcome to the May 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This edition provides articles on such topics as the recent approval of a JAK2 RGQ PCR kit to evaluate suspected polycythemia vera, the management of venous thromboembolism in myeloproliferative neoplasms, and insight into how downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.

This month I'd like to highlight Chapter 4 of the expert video roundtable I moderated, as it discusses the importance of monitoring for polypharmacy and drug interactions as a means to enhance patient medication adherence.

Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

 

Lindsey Lyle, MS, PA-C

Instructor, Medicine-Hematology

University of Colorado, Anschutz Medical Campus

April 2017

Dear Colleague,

Welcome to the April 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This month I'd like to highlight one of the most important parts of our roundtable discussion on MPNs: an interview with Tina, a very special patient I got to know well during her first three years of treatment. Tina graciously agreed to share her story from diagnosis up through her current management phase, shedding light on how she’s worked with her treatment team to get the best results possible. 

This edition also provides articles on such topics as the prevalence of anxiety and distress among patients with BCR-ABL-negative myeloproliferative neoplasms, genetic profiling as the basis of a groundbreaking myelofibrosis study, and the prognostic impact of bone marrow fibrosis in polycythemia vera. 

Please share this newsletter with your colleagues, and don’t hesitate to get in touch with me through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com, at any time.

Until next time, watch the video of Tina’s story and take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

 

Lindsey Lyle, MS, PA-C

Instructor, Medicine-Hematology

University of Colorado, Anschutz Medical Campus

February 2017

Dear Colleague,

Welcome to the February 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This month I'd like to highlight Chapter 6 of the expert video roundtable I moderated, as it discusses current treatment approaches for MPNs.

You’ll also find links to articles on such topics as the significant effects of high symptom burden in patients with myeloproliferative disorders; how genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndromes; and the significance of the differences in hematologic and clinical features between essential thrombocythemia cases with JAK2- or CALR-mutations.

Please share this newsletter with your colleagues, and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

 Lindsey Lyle, MS, PA-C
Instructor, Medicine-Hematology
University of Colorado, Anschutz Medical Campus

January 2017

Dear Colleague,

Welcome to the January 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This edition provides articles on such topics as improved 5-year survival with early use of ruxolitinib; the potential prognostic power of elevated circulating nucleosomes, and the risk of venous thromboembolism in pregnant women with essential thrombocythemia.

This month I'd like to highlight Chapter 3 of the expert video roundtable I moderated, as it emphasizes the value of obtaining bone marrow fibrosis grades to assist in determining appropriate treatment approaches in patients with primary myelofibrosis.

Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of The Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.


Lindsey Lyle, MS, PA-C
Instructor, Medicine-Hematology
University of Colorado, Anschutz Medical Campus 

November 2016

Dear Colleague,

Welcome to the November edition of our newsletter, Updates on Myeloproliferative Neoplasms. This edition provides articles on topics such as the promising results of lenalidomide in patients with myelofibrosis with myeloid metaplasia; successful pregnancies in women with myeloproliferative neoplasms; and findings from a landmark survey on the significant impact of myeloproliferative neoplasms on the overall health and productivity of patients.

This month I’d like to highlight Chapter 5 of the expert video roundtable, as it provides some newer clinical pearls you may not have heard about yet. The video also emphasizes the value of a collaborative team approach when managing patients with cancer.

Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.


Lindsey Lyle, MS, PA-C
Instructor, Medicine-Hematology
University of Colorado, Anschutz Medical Campus 

October 2016

Dear Colleague,

Welcome to the October edition of MPN Updates! In this issue, we provide highlights that emanated from Perspectives on the Collaborative Management of Myeloproliferative Neoplasms, a recent roundtable discussion held in Houston, Texas. Panelists discussed current topics such as the updated 2016 WHO classification of myeloproliferative neoplasms and therapies available for managing complications related to the disease processes. You can view the full video here.

This edition also provides articles on such topics as the utilization of ruxolitinib to control hematocrit levels in polycythemia vera, chromothripsis as a recurrent genomic abnormality in patients with high-risk myelodysplastic syndromes, and bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. In our next edition, we plan to provide you with findings from the 7th International Conference on Myeloproliferative Neoplasms being held in Estoril, Portugal.

Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.

Lindsey Lyle, MS, PA-C
Instructor, Medicine-Hematology
University of Colorado, Anschutz Medical Campus

August 2016

Dear Colleagues,

It is estimated that slightly more than 300,000 Americans have been diagnosed with myeloproliferative neoplasms (MPNs). The three classic forms of BCR-ABL negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF), with PV being the most prevalent. Although MPNs can strike anyone at any age, most patients are afflicted in the sixth decade of life or later.

Although outside of allogeneic stem cell transplant, there is no cure for MPNs, there are medical therapies that can inhibit promiscuous signaling pathways caused by genetic mutations, reduce risk of complications, and improve symptom burden. In addition, clinical studies are underway to explore additional therapies.

Here, the Journal of the Advanced Practitioner in Oncology (JADPRO) presents Myeloproliferative Neoplasms (MPN) Updates, a monthly educational newsletter and enduring resource for advanced practitioners. As the editor of the program, I will share articles and news items containing the latest in treatment and management strategies. In the near future, we’ll take a look at the most relevant and potentially practice-changing results to come out of the 2016 ASH® Meeting on Hematologic Malignancies. In addition, in our next edition we’ll be presenting a video roundtable discussion with several of my distinguished colleagues on current issues in MPN.

Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at editor@advancedpractitioner.com at any time.

Until next time, take a look at the links I’ve gathered for you here. I hope you find this to be a useful resource in your practice!

Lindsey Lyle, MS, PA-C
Instructor, Medicine-Hematology
University of Colorado, Anschutz Medical Campus

click me